Antibacterial compounds

1. A compound selected from the compounds of formula (I); pharmaceutically acceptable salts of compounds of formula (I), and pharmaceutically acceptable N-oxides of compounds of formula (I), wherein formula (I) is:

wherein:

R V and R W are hydrogen or R V and R W together are a bond;

R A is an optionally substituted bicyclic carbocyclic or heterocyclic ring system of structure:

containing 0-3 heteroatoms in each ring in which:

at least one of rings (x) and (y) is aromatic;

one of Z 4 and Z 5 is C or N and the other is C;

Z 3 is N, NR 13 , O, S(O) x , CO, CR 1 or CR 1 R 1a ;

Z 1 and Z 2 are independently a 2 or 3 atom linker group each atom of which is independently selected from N, NR 13 , O, S(O) x , CO, CR 1 and CR 1 R 1a ; such that each ring is independently substituted with 0-3 groups R 1 and/or R 1a ;

R 1 and R 1a are independently selected from hydrogen; hydroxy; (C 1-6 ) alkoxy optionally substituted by (C 1-6 )alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C 1-6 )alkyl, acyl or (C 1-6 )alkylsulphonyl groups, CONH 2 , hydroxy, (C 1-6 )alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C 1-6 )alkylsulphonyloxy; (C 1-6 )alkoxy-substituted (C 1-6 )alkyl; hydroxy (C 1-6 )alkyl; halogen; (C 1-6 )alkyl; (C 1-6 )alkylthio; trifluoromethyl; trifluoromethoxy; cyano; carboxy; nitro; azido; acyl; acyloxy; acylthio; (C 1-6 )alkylsulphonyl; (C 1-6 )alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C 1-6 )alkyl, acyl or (C 1-6 )alkylsulphonyl groups, or when Z 3 and the adjacent atom are CR 1 and CR 1a , R 1 and R 1a may together represent (C 1-2 )alkylenedioxy,

wherein acyl is (C 1-6 )alkoxycarbonyl, formyl, or (C 1-6 )alkylcarbonyl;

provided that R 1 and R 1a , on the same carbon atom are not both optionally substituted hydroxyl or amino;

provided that

(i) when R A is optionally substituted quinolin-4-yl:

it is unsubstituted in the 6-position; or

it is substituted by at least one hydroxy (C 1-6 )alkyl, cyano or carboxy group at the 2-, 5-, 6-, 7- or 8-position; or

it is substituted by at least one trifluoromethoxy group; or

R 3 is halogen;

(ii) when R A is optionally substituted quinazolin-4-yl, cinnolin-4-yl, 1,5-naphthyridin-4-yl, 1,7-naphthyridin-4-yl or 1,8-naphthyridin-4-yl:

it is substituted by at least one hydroxy (C 1-6 )alkyl, cyano or carboxy group at the 2-, 5-, 6-, 7- or 8-position as available; or

it is substituted by at least one trifluoromethoxy group; or

R 3 is halogen;

R 2 is hydrogen, or (C 1-4 )alkyl or (C 2-4 )alkenyl optionally substituted with 1 to 3 groups selected from:

amino optionally substituted by one or two (C 1-4 )alkyl groups; carboxy; (C 1-4 )alkoxycarbonyl; (C 1-4 )alkylcarbonyl; (C 2-4 )alkenyloxycarbonyl; (C 2-4 )alkenylcarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C 1-4 )alkyl, hydroxy(C 1-4 )alkyl, aminocarbonyl(C 1-4 )alkyl, (C 2-4 )alkenyl, (C 1-4 )alkylsulphonyl, trifluoromethylsulphonyl, (C 2-4 )alkenylsulphonyl, (C 1-4 )alkoxycarbonyl, (C 1-4 )alkylcarbonyl, (C 2-4 )alkenyloxycarbonyl or (C 2-4 )alkenylcarbonyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R 10 ; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R 10 ; 5-oxo-1,2,4-oxadiazol-3-yl; halogen; (C 1-4 )alkylthio; trifluoromethyl; hydroxy optionally substituted by (C 1-4 )alkyl, (C 2-4 )alkenyl, (C 1-4 )alkoxycarbonyl, (C 1-4 )alkylcarbonyl, (C 2-4 )alkenyloxycarbonyl, (C 2-4 )alkenylcarbonyl; oxo; (C 1-4 )alkylsulphonyl; (C 2-4 )alkenylsulphonyl; or (C 1-4 )aminosulphonyl wherein the amino group is optionally substituted by (C 1-4 )alkyl or (C 2-4 )alkenyl;

R 3 is hydrogen; or

when R V and R W are a bond, R 3 is in the 2-, 3- or 4-position and when R v and R w are not a bond, R 3 is in the 1-, 2-, 3- or 4-position and R 3 is:

carboxy; (C 1-6 )alkoxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C 1-6 )alkyl, hydroxy(C 1-6 )alkyl, aminocarbonyl(C 1-6 )alkyl, (C 2-6 )alkenyl, (C 1-6 )alkylsulphonyl, trifluoromethylsulphonyl, (C 2-6 )alkenylsulphonyl, (C 1-6 )alkoxycarbonyl, (C 1-6 )alkylcarbonyl, (C 2-6 )alkenyloxycarbonyl or (C 2-6 )alkenylcarbonyl and optionally further substituted by (C 1-6 )alkyl, hydroxy(C 1-6 )alkyl, aminocarbonyl(C 1-6 )alkyl or (C 2-6 )alkenyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R 10 ; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R 10 ; or 5-oxo-1,2,4-oxadiazol-3-yl; or

(C 1-4 )alkyl or ethenyl optionally substituted with any of the groups listed above for R 3 and/or 0 to 2 groups R 12 independently selected from:

halogen; (C 1-6 )alkylthio; trifluoromethyl; (C 1-6 )alkoxycarbonyl; (C 1-6 )alkylcarbonyl; (C 2-6 )alkenyloxycarbonyl; (C 2-6 )alkenylcarbonyl; hydroxy optionally substituted by (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 1-6 )alkoxycarbonyl, (C 1-6 )alkylcarbonyl, (C 2-6 )alkenyloxycarbonyl, (C 2-6 )alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 1-6 )alkylcarbonyl or (C 2-6 )alkenylcarbonyl; amino optionally mono- or disubstituted by (C 1-6 )alkoxycarbonyl, (C 1-6 )alkylcarbonyl, (C 2-6 )alkenyloxycarbonyl, (C 2-6 )alkenylcarbonyl, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 1-6 )alkylsulphonyl, (C 2-6 )alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (C 1-6 )alkyl or (C 2-6 )alkenyl; aminocarbonyl wherein the amino group is optionally substituted by (C 1-6 )alkyl, hydroxy(C 1-6 )alkyl, aminocarbonyl(C 1-6 )alkyl, (C 2-6 )alkenyl, (C 1-6 )alkoxycarbonyl, (C 1-6 )alkylcarbonyl, (C 2-6 )alkenyloxycarbonyl or (C 2-6 )alkenylcarbonyl and optionally further substituted by (C 1-6 )alkyl, hydroxy(C 1-6 )alkyl, aminocarbonyl(C 1-6 )alkyl or (C 2-6 )alkenyl; oxo; (C 1-6 )alkylsulphonyl; (C 2-6 )alkenylsulphonyl; or (C 1-6 )aminosulphonyl wherein the amino group is optionally substituted by (C 1-6 )alkyl or (C 2-6 )alkenyl; or

hydroxy optionally substituted by (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 1-6 )alkoxycarbonyl, (C 1-6 )alkylcarbonyl, (C 2-6 )alkenyloxycarbonyl, (C 2-6 )alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 1-6 )alkylcarbonyl or (C 2-6 )alkenylcarbonyl; or

amino optionally mono- or disubstituted by (C 1-6 )alkoxycarbonyl, (C 1-6 )alkylcarbonyl, (C 2-6 )alkenyloxycarbonyl, (C 2-6 )alkenylcarbonyl, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 1-6 )alkylsulphonyl, (C 2-6 )alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (C 1-6 )alkyl or (C 2-6 )alkenyl; or

halogen;

provided that when R 3 is in the 4-position it is not optionally substituted hydroxyl or amino or halogen;

in addition when R 3 is disubstituted with a hydroxy or amino containing substituent and a carboxy containing substituent these may optionally together form a cyclic ester or amide linkage, respectively;

R 10 is selected from (C 1-4 )alkyl and (C 2-4 )alkenyl either of which may be optionally substituted by a group R 12 as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 1-6 )alkylsulphonyl, trifluoromethylsulphonyl, (C 2-6 )alkenylsulphonyl, (C 1-6 )alkoxycarbonyl, (C 1-6 )alkylcarbonyl, (C 2-6 )alkenyloxycarbonyl or (C 2-6 )alkenylcarbonyl and optionally further substituted by (C 1-6 )alkyl or (C 2-6 )alkenyl; (C 1-6 )alkylsulphonyl; trifluoromethylsulphonyl; (C 2-6 )alkenylsulphonyl; (C 1-6 )alkoxycarbonyl; (C 1-6 )alkylcarbonyl; (C 2-6 )alkenyloxycarbonyl; and (C 2-6 )alkenylcarbonyl;

R 4 is a group —U—R 5 2 where R 5 2 is a group,

each of R 14 and R 15 is independently selected from: H; (C 1-4 )alkylthio; halo; carboxy(C 1-4 )alkyl; halo(C 1-4 )alkoxy; halo(C 1-4 )alkyl; (C 1-4 )alkyl; (C 2-4 )alkenyl; (C 1-4 )alkoxycarbonyl; formyl; (C 1-4 )alkylcarbonyl; (C 2-4 )alkenyloxycarbonyl; (C 2-4 )alkenylcarbonyl; (C 1-4 )alkylcarbonyloxy; (C 1-4 )alkoxycarbonyl(C 1-4 )alkyl; hydroxy; hydroxy(C 1-4 )alkyl; mercapto(C 1-4 )alkyl; (C 1-4 )alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in R 3 ; (C 1-4 )alkylsulphonyl; (C 2-4 )alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C 1-4 )alkyl or (C 2-4 )alkenyl; aryl; aryl(C 1-4 )alkyl; aryl(C 1-4 )alkoxy;

each R 13 is independently H; trifluoromethyl; (C 1-4 )alkyl optionally substituted by hydroxy, carboxy, (C 1-6 )alkoxycarbonyl, (C 1-6 )alkoxy, (C 1-6 )alkylthio, halo or trifluoromethyl; (C 2-4 )alkenyl; aryl; aryl (C 1-4 )alkyl; arylcarbonyl; heteroarylcarbonyl; (C 1-4 )alkoxycarbonyl; (C 1-4 )alkylcarbonyl; formyl; (C 1-6 )alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C 1-4 )alkoxycarbonyl, (C 1-4 )alkylcarbonyl, (C 2-4 )alkenyloxycarbonyl, (C 2-4 )alkenylcarbonyl, (C 1-4 )alkyl or (C 2-4 )alkenyl and optionally further substituted by (C 1-4 )alkyl or (C 2-4 )alkenyl;

each x is independently 0, 1 or 2;

U is CO, SO 2 or CH 2 ;

n is 0 or 1 and AB is NR 11 CO, CONR 11 , CO—CR 8 R 9 , CR 6 R 7 —CO, O—CR 8 R 9 , CR 6 R 7 —O, NHR 11 —CR 8 R 9 , CR 6 R 7 —NHR 11 , NR 11 SO 2 , CR 6 R 7 —SO 2 or CR 6 R 7 —CR 8 R 9 ,

provided that when R v and R w are a bond and n=0, B is not NR 11 , O or SO 2 ,

or n is 0 and AB is NH—CO—NH or NH—CO—O and R V /R W are not a bond;

or n is 0 and AB is CR 6 R 7 SO 2 NR 2 , CR 6 R 7 CONR 2 or CR 6 R 7 CH 2 NR 2 and R V /R W are not a bond;

provided that R 6 and R 7 , and R 8 and R 9 are not both optionally substituted hydroxy or amino;

and wherein:

each of R 6 , R 7 , R 8 and R 9 is independently selected from: H; (C 1-6 )alkoxy; (C 1-6 )alkylthio; halo; trifluoromethyl; azido; (C 1-6 )alkyl; (C 2-6 )alkenyl; (C 1-6 )alkoxycarbonyl; (C 1-6 )alkylcarbonyl; (C 2-6 )alkenyloxycarbonyl; (C 2-6 )alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R 3 ; (C 1-6 )alkylsulphonyl; (C 2-6 )alkenylsulphonyl; or (C 1-6 )aminosulphonyl wherein the amino group is optionally substituted by (C 1-6 )alkyl or (C 2-6 )alkenyl;

or R 6 and R 8 together represent a bond and R 7 and R 9 are as above defined;

and each R 11 is independently H; trifluoromethyl; (C 1-6 )alkyl; (C 2-6 )alkenyl; (C 1-6 )alkoxycarbonyl; (C 1-6 )alkylcarbonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C 1-6 )alkoxycarbonyl, (C 1-6 )alkylcarbonyl, (C 2-6 )alkenyloxycarbonyl, (C 2-6 )alkenylcarbonyl, (C 1-6 )alkyl or (C 2-6 )alkenyl and optionally further substituted by (C 1-6 )alkyl or (C 2-6 )alkenyl;

or where one of R 3 and R 6 , R 7 , R 8 or R 9 contains a hydroxy or amino group they may together form a cyclic ester or amide linkage or where R 3 contains a carboxy group and A or B is NH they may be condensed to form a cyclic amide.

2. The compound according to claim 1 wherein R A is optionally substituted isoquinolin-5-yl, quinolin-8-yl, thieno[3,2-b]pyridin-7-yl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl, quinoxalin-5-yl, isoquinolin-8-yl, [1,6]-naphthyridin-4-yl, 1,2,3,4-tetrahydroquinoxalin-5-yl or 1,2-dihydroisoquinoline-8-yl.

3. The compound according to claim 1 wherein R 1 is hydrogen, methoxy, methyl, cyano or halogen and R 1a is H.

4. The compound according to claim 1 wherein R 2 is hydrogen.

5. The compound according to claim 1 wherein R 3 is hydrogen, fluoro or hydroxy substituted in the 1-or 3-position.

6. The compound according to claim 1 wherein n is 0 and either A and B are both CH 2 , A is CHOH or CH 2 and B is CH 2 or A is NH and B is CO.

7. The compound according to claim 1 wherein R 5 2 is 2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl.

8. A compound selected from:

Cis-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-hydroxy-N-(2-methyl-8-quinolinyl)cyclohexanecarboxamide;

trans-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-N-(2-methyl-8-quinolinyl)cyclohexanecarboxamide;

(1R,3S,4R)-N-(2-cyano-8-quinolinyl)-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-hydroxycyclohexanecarboxamide;

cis-N-(2-cyano-8-quinolinyl)-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-hydroxycyclohexanecarboxamide;

(1R3R4R)-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-(methyloxy)-N-(2-methyl-8-quinolinyl)cyclohexanecarboxamide;

cis-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-hydroxy-N-[3-(methyloxy-5-quinoxalinyl]cyclohexanecarboxamide;

cis-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-hydroxy-N-(3-methyl-5-quinoxalinyl)cyclohexanecarboxamide;

pharmaceutically acceptable salts of the foregoing compounds; and

pharmaceutically acceptable N-oxides of the foregoing compounds.

9. A method of treatment of bacterial infection due to Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Haemophilus influenzae, E. coli , or Moraxella catarrhalis in mammals, which method comprises the administration to a mammal in need of such treatment an effective amount of the compound according to claim 1 .

10. A pharmaceutical composition comprising the compound according to claim 1 , and a pharmaceutically acceptable carrier.

11. A process for preparing a compound according to claim 1 , which process comprises reacting a compound of formula (IV) with a compound of formula (V):

wherein n is as defined in formula (I); Z 1′ , Z 2′ , Z 3′ R 1′ and R 3′ are Z 1 , Z 2 , Z 3 , R 1 and R 3 as defined in formula (I) or groups convertible thereto; Z 4 , Z 5 , R v and R w are as defined in formula (I);

Q 1 is NR 2′ R 4′ or a group convertible thereto wherein R 2′ and R 4′ are R 2 and R 4 as defined in formula (I) or groups convertible thereto and Q 2 is H or R 3′ or Q 1 and Q 2 together form an optionally protected oxo group;

and X and Y may be the following combinations:

(i) one of X and Y is CO 2 R y and the other is CH 2 CO 2 R x ;

(ii) X is CHR 6 R 7 and Y is C(═O)R 9 ;

(iii) X is CR 7 ═PR z 3 and Y is C(═O)R 9 ;

(iv) X is C(═O)R 7 and Y is CR 9 ═PR z 3 ;

(v) one of Y and X is COW and the other is NHR 11′ , NCO or NR 11′ COW;

(vi) X is NHR 11 and Y is C(═O)R 8 or X is C(═O)R 6 and Y is NHR 11′ ;

(vii) X is NHR 11′ and Y is CR 8 R 9 ;

(viii) X is W or OH and Y is CH 2 OH;

(ix) X is NHR 11′ and Y is SO 2 W;

(x) one of X and Y is (CH 2 ) p —W and the other is (CH 2 ) q NHR 11′ , (CH 2 ) q OH, (CH 2 ) q SH or (CH 2 ) q SCOR x where p+q=1;

(xi) one of X and Y is OH and the other is —CH═N 2 ;

(xii) X is NCO and Y is OH or NH 2 ;

(xiii) X is CR 6 R 7 SO 2 W, A′COW, CR 6 ═CH 2 or oxirane and Y is NHR 2′ ;

(xiv) X is W and Y is CONHR 11 or OCONH 2

(xv) X is W and Y is —C≡CH followed by hydrogenation of the intermediate —C≡C— group;

in which W is a leaving group; R x and R y are (C 1-6 )alkyl; R z is aryl or (C 1-6 )alkyl; A′ and NR 11′ are A and NR 11 as defined in formula (I), or groups convertible thereto; and oxirane is:

wherein R 6 , R 8 and R 9 are as defined in formula (I);

and thereafter optionally or as necessary converting Q 1 and Q 2 to NR 2′ R 4′ ; converting A′, Z 1′ , Z 2′ , Z 3′ , R 1′ , R 2′ , R 3′ , R 4′ and NR 11′ to A, Z 1 , Z 2 , Z 3 , R 1 , R 2 , R 3 , R 4 and NR 11′ ; converting A-B to other A-B, interconverting R v , R w , R 1 , R 2 , R 3 and/or R 4 , and/or forming a pharmaceutically acceptable derivative thereof.

12. A method of treatment of bacterial infection due to Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Haemophilus influenzae, E. coli , or Moraxella catarrhalis in mammals, which method comprises the administration to a mammal in need of such treatment an effective amount of the compound according to claim 8 .

13. A pharmaceutical composition comprising the compound according to claim 8 , and a pharmaceutically acceptable carrier.

14. The compound according to claim 1 wherein R A is 2-methyl-1-oxo-1,2-dihydro-isoquinolin-8yl.

15. The compound according to claim 1 wherein R A is 3-methoxy-quinoxalin-5-yl.

16. The compound according to claim 1 wherein the compound is a compound of formula (I).

17. A method of treatment of bacterial infection due to Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Haemophilus influenzae, E. coli , or Moraxella catarrhalis in mammals, which method comprises the administration to a mammal in need of such treatment an effective amount of the compound according to claim 16 .

18. A pharmaceutical composition comprising the compound according to claim 16 , and a pharmaceutically acceptable carrier.

19. The compound according to claim 1 wherein the compound is a pharmaceutically acceptable salt of a compound of formula (I).

20. A method of treatment of bacterial infection due to Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Haemophilus influenzae, E. coli , or Moraxella catarrhalis in mammals, which method comprises the administration to a mammal in need of such treatment an effective amount of the compound according to claim 19 .

21. A pharmaceutical composition comprising the compound according to claim 19 , and a pharmaceutically acceptable carrier.

22. A compound selected from:

Cis-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-hydroxy-N-(2-methyl-8-quinolinyl)cyclohexanecarboxamide hydrochloride;

trans-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-N-(2-methyl-8-quinolinyl)cyclohexanecarboxamide hydrochloride;

(1R,3S,4R)-N-(2-cyano-8-quinolinyl)-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-hydroxycyclohexanecarboxamide hydrochloride;

cis-N-(2-cyano-8-quinolinyl)-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-hydroxycyclohexanecarboxamide hydrochloride;

(1R3R4R)-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-3-(methyloxy)-N-(2-methyl-8-quinolinyl)cyclohexanecarboxamide hydrochloride;

cis-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-hydroxy-N-[3-(methyloxy-5-quinoxalinyl]cyclohexanecarboxamide hydrochloride;

cis-4-[(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-hydroxy-N-(3-methyl-5-quinoxalinyl)cyclohexanecarboxamide hydrochloride.

23. A method of treatment of bacterial infection due to Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Haemophilus influenzae, E. coli , or Moraxella catarrhalis in mammals, which method comprises the administration to a mammal in need of such treatment an effective amount of the compound according to claim 22 .

24. A pharmaceutical composition comprising the compound according to claim 22 , and a pharmaceutically acceptable carrier.